Top

Published in:

01-08-2014 | Original Article

Role of cytolytic impairment of natural killer and natural killer T-cell populations in rheumatoid arthritis

Authors: Ashish Aggarwal, Aman Sharma, Archana Bhatnagar

Published in: Clinical Rheumatology | Issue 8/2014

Abstract

Innate immunity has been widely accepted as one of the major cause for the alteration of immune system and progression of autoimmune diseases. Natural killer (NK) cells and natural killer T (NKT) cells have not been explored in clinical studies for their cytolytic components in association with rheumatoid arthritis (RA). The literature available for these potential candidates is controversial in terms of their protective or pathogenic role in disease severity of RA. Present study explained the role of NK and NKT cell populations and intracellular expression of caspases, perforin, granzymes A and B in the pathogenesis of RA in patients. DAS28 score was measured as the disease severity. Immunochemical parameters were studied by using monoclonal antibodies (mAbs) against different cell types in flow cytometry. Results indicated that that whatsoever is the change in percentage cell populations, ratio of NK and NKT cell populations always remained poised even in the disease state. Reactive oxygen species (ROS) levels were elevated with increased intracellular active caspase-3, perforin and granzyme expression in RA patients. Their elevated expressions were positively correlated with DAS28 suggesting the pathogenic role in RA. The expressions of pro-inflammatory cytokines were enhanced while the anti-inflammatory cytokine expressions were diminished in the patients. Present study may point towards futuristic therapeutic targets which can fascinate the pharmaceutical industries to selectively target these molecules in designing the therapeutic strategy of RA patients.

Maini RN (1998) Rheumatoid arthritis. A paradigm of inflammatory disease of the musculoskeletal system. Acta Orthop Scand Suppl 281:6–13PubMed

Klareskog L, Padyukov L, Ronnelid J, Alfredsson L (2006) Genes, environment and immunity in the development of rheumatoid arthritis. Curr Opin Immunol 18(6):650–655. doi:10.1016/j.coi.2006.06.004 PubMedCrossRef

Vivier E, Nunes JA, Vely F (2004) Natural killer cell signaling pathways. Science 306(5701):1517–1519. doi:10.1126/science.1103478 PubMedCrossRef

Flodstrom M, Shi FD, Sarvetnick N, Ljunggren HG (2002) The natural killer cell — friend or foe in autoimmune disease? Scand J Immunol 55(5):432–441PubMedCrossRef

Kang H, Han BS, Kim SJ, Oh YJ (2012) Mechanisms to prevent caspase activation in rotenone-induced dopaminergic neurodegeneration: role of ATP depletion and procaspase-9 degradation. Apoptosis. doi:10.1007/s10495-012-0699-0 PubMedCentral

Heibein JA, Goping IS, Barry M, Pinkoski MJ, Shore GC, Green DR, Bleackley RC (2000) Granzyme B-mediated cytochrome c release is regulated by the Bcl-2 family members bid and Bax. J Exp Med 192(10):1391–1402PubMedCentralPubMedCrossRef

Ronday HK, van der Laan WH, Tak PP, de Roos JA, Bank RA, TeKoppele JM, Froelich CJ, Hack CE, Hogendoorn PC, Breedveld FC, Verheijen JH (2001) Human granzyme B mediates cartilage proteoglycan degradation and is expressed at the invasive front of the synovium in rheumatoid arthritis. Rheumatology (Oxford) 40(1):55–61CrossRef

Romero V, Andrade F (2008) Non-apoptotic functions of granzymes. Tissue Antigens 71(5):409–416. doi:10.1111/j.1399-0039.2008.01013.x PubMedCrossRef

Metkar SS, Menaa C, Pardo J, Wang B, Wallich R, Freudenberg M, Kim S, Raja SM, Shi L, Simon MM, Froelich CJ (2008) Human and mouse granzyme A induce a proinflammatory cytokine response. Immunity 29(5):720–733. doi:10.1016/j.immuni.2008.08.014 PubMedCrossRef

10.

Froelich CJ, Zhang X, Turbov J, Hudig D, Winkler U, Hanna WL (1993) Human granzyme B degrades aggrecan proteoglycan in matrix synthesized by chondrocytes. J Immunol 151(12):7161–7171PubMed

11.

Chowdhury D, Lieberman J (2008) Death by a thousand cuts: granzyme pathways of programmed cell death. Annu Rev Immunol 26:389–420. doi:10.1146/annurev.immunol.26.021607.090404 PubMedCentralPubMedCrossRef

12.

Sower LE, Klimpel GR, Hanna W, Froelich CJ (1996) Extracellular Activities of Human Granzymes. Cell Immunol 171(1):159–163CrossRef

13.

de Jager W, Vastert SJ, Beekman JM, Wulffraat NM, Kuis W, Coffer PJ, Prakken BJ (2009) Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 60(9):2782–2793. doi:10.1002/art.24750 PubMedCrossRef

14.

Shegarfi H, Naddafi F, Mirshafiey A (2012) Natural killer cells and their role in rheumatoid arthritis: friend or foe? Sci World J 2012:491974. doi:10.1100/2012/491974 CrossRef

15.

Flodstrom-Tullberg M, Bryceson YT, Shi FD, Hoglund P, Ljunggren HG (2009) Natural killer cells in human autoimmunity. Curr Opin Immunol 21(6):634–640. doi:10.1016/j.coi.2009.09.012 PubMedCrossRef

16.

Lo CK, Lam QL, Sun L, Wang S, Ko KH, Xu H, Wu CY, Zheng BJ, Lu L (2008) Natural killer cell degeneration exacerbates experimental arthritis in mice via enhanced interleukin-17 production. Arthritis Rheum 58(9):2700–2711. doi:10.1002/art.23760 PubMedCrossRef

17.

Soderstrom K, Stein E, Colmenero P, Purath U, Muller-Ladner U, de Matos CT, Tarner IH, Robinson WH, Engleman EG (2010) Natural killer cells trigger osteoclastogenesis and bone destruction in arthritis. Proc Natl Acad Sci U S A 107(29):13028–13033. doi:10.1073/pnas.1000546107 PubMedCentralPubMedCrossRef

18.

Aramaki T, Ida H, Izumi Y, Fujikawa K, Huang M, Arima K, Tamai M, Kamachi M, Nakamura H, Kawakami A, Origuchi T, Matsuoka N, Eguchi K (2009) A significantly impaired natural killer cell activity due to a low activity on a per-cell basis in rheumatoid arthritis. Mod Rheumatol 19(3):245–252. doi:10.1007/s10165-009-0160-6 PubMedCrossRef

19.

Lunemann A, Lunemann JD, Munz C (2009) Regulatory NK-cell functions in inflammation and autoimmunity. Mol Med 15(9–10):352–358. doi:10.2119/molmed.2009.00035 PubMedCentralPubMed

20.

Park YW, Kee SJ, Cho YN, Lee EH, Lee HY, Kim EM, Shin MH, Park JJ, Kim TJ, Lee SS, Yoo DH, Kang HS (2009) Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus. Arthritis Rheum 60(6):1753–1763. doi:10.1002/art.24556 PubMedCrossRef

21.

Paust S, Senman B, von Andrian UH (2010) Adaptive immune responses mediated by natural killer cells. Immunol Rev 235(1):286–296. doi:10.1111/j.0105-2896.2010.00906.x PubMedCentralPubMed

22.

Godfrey DI, Kinder SJ, Silvera P, Baxter AG (1997) Flow cytometric study of T cell development in NOD mice reveals a deficiency in alphabetaTCR+CDR−CD8− thymocytes. J Autoimmun 10(3):279–285PubMedCrossRef

23.

Peng SL (2006) Fas (CD95)-related apoptosis and rheumatoid arthritis. Rheumatology (Oxford) 45(1):26–30. doi:10.1093/rheumatology/kei113 CrossRef

24.

Ivashchenko O, Van Veldhoven PP, Brees C, Ho YS, Terlecky SR, Fransen M (2011) Intraperoxisomal redox balance in mammalian cells: oxidative stress and interorganellar cross-talk. Mol Biol Cell 22(9):1440–1451. doi:10.1091/mbc.E10-11-0919 PubMedCentralPubMedCrossRef

25.

Kregel KC, Zhang HJ (2007) An integrated view of oxidative stress in aging: basic mechanisms, functional effects, and pathological considerations. Am J Physiol Regul Integr Comp Physiol 292(1):R18–R36. doi:10.1152/ajpregu.00327.2006 PubMedCrossRef

26.

Shah D, Kiran R, Wanchu A, Bhatnagar A (2010) Oxidative stress in systemic lupus erythematosus: relationship to Th1 cytokine and disease activity. Immunol Lett 129(1):7–12. doi:10.1016/j.imlet.2010.01.005 PubMedCrossRef

27.

Shah D, Aggarwal A, Bhatnagar A, Kiran R, Wanchu A (2011) Association between T lymphocyte sub-sets apoptosis and peripheral blood mononuclear cells oxidative stress in systemic lupus erythematosus. Free Radic Res 45(5):559–567. doi:10.3109/10715762.2011.555765 PubMedCrossRef

28.

Shah D, Wanchu A, Bhatnagar A (2011) Interaction between oxidative stress and chemokines: possible pathogenic role in systemic lupus erythematosus and rheumatoid arthritis. Immunobiology 216(9):1010–1017. doi:10.1016/j.imbio.2011.04.001 PubMedCrossRef

29.

Minhas U, Minz R, Das P, Bhatnagar A (2012) Therapeutic effect of Withania somnifera on pristane-induced model of SLE. Inflammopharmacology 20(4):195–205. doi:10.1007/s10787-011-0102-8 PubMedCrossRef

30.

Mellqvist UH, Hansson M, Brune M, Dahlgren C, Hermodsson S, Hellstrand K (2000) Natural killer cell dysfunction and apoptosis induced by chronic myelogenous leukemia cells: role of reactive oxygen species and regulation by histamine. Blood 96(5):1961–1968PubMed

31.

Winyard PG, Ryan B, Eggleton P, Nissim A, Taylor E, Lo Faro ML, Burkholz T, Szabo-Taylor KE, Fox B, Viner N, Haigh RC, Benjamin N, Jones AM, Whiteman M (2011) Measurement and meaning of markers of reactive species of oxygen, nitrogen and sulfur in healthy human subjects and patients with inflammatory joint disease. Biochem Soc Trans 39(5):1226–1232. doi:10.1042/BST0391226 PubMedCrossRef

32.

Kurien BT, Scofield RH (2008) Autoimmunity and oxidatively modified autoantigens. Autoimmun Rev 7(7):567–573. doi:10.1016/j.autrev.2008.04.019 PubMedCentralPubMedCrossRef

33.

Ferrer PE, Frederick P, Gulbis JM, Dewson G, Kluck RM (2012) Translocation of a bak C-terminus mutant from cytosol to mitochondria to mediate cytochrome C release: implications for bak and bax apoptotic function. PLoS One 7(3):e31510. doi:10.1371/journal.pone.0031510 PubMedCentralPubMedCrossRef

34.

Taylor RC, Cullen SP, Martin SJ (2008) Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 9(3):231–241. doi:10.1038/nrm2312 PubMedCrossRef

35.

Caligiuri MA (2008) Human natural killer cells. Blood 112(3):461–469. doi:10.1182/blood-2007-09-077438 PubMedCentralPubMedCrossRef

36.

Tarazona R, DelaRosa O, Peralbo E, Casado JG, Pena J, Solana R (2003) Human NKT cells in health and disease. Immunologia 22(4):359–370

37.

Vastert SJ, van Wijk R, D'Urbano LE, de Vooght KM, de Jager W, Ravelli A, Magni-Manzoni S, Insalaco A, Cortis E, van Solinge WW, Prakken BJ, Wulffraat NM, de Benedetti F, Kuis W (2010) Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford) 49(3):441–449. doi:10.1093/rheumatology/kep418 CrossRef

38.

Cho BA, Sim JH, Park JA, Kim HW, Yoo WH, Lee SH, Lee DS, Kang JS, Hwang YI, Lee WJ, Kang I, Lee EB, Kim HR (2012) Characterization of effector memory CD8+ T cells in the synovial fluid of rheumatoid arthritis. J Clin Immunol 32(4):709–720. doi:10.1007/s10875-012-9674-3 PubMedCrossRef

39.

Stabler T, Piette JC, Chevalier X, Marini-Portugal A, Kraus VB (2004) Serum cytokine profiles in relapsing polychondritis suggest monocyte/macrophage activation. Arthritis Rheum 50(11):3663–3667. doi:10.1002/art.20613 PubMedCrossRef

40.

Dinarello CA (2007) Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol 27(1):98–114. doi:10.1016/j.semnephrol.2006.09.013 PubMedCrossRef

41.

Lin NY, Beyer C, Giessl A, Kireva T, Scholtysek C, Uderhardt S, Munoz LE, Dees C, Distler A, Wirtz S, Kronke G, Spencer B, Distler O, Schett G, Distler JH (2013) Autophagy regulates TNFalpha-mediated joint destruction in experimental arthritis. Ann Rheum Dis 72(5):761–768. doi:10.1136/annrheumdis-2012-201671 PubMedCrossRef

42.

Haugeberg G, Conaghan PG, Quinn M, Emery P (2009) Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study. Ann Rheum Dis 68(12):1898–1901. doi:10.1136/ard.2008.106484 PubMedCrossRef

43.

Zhang W, Cong XL, Qin YH, He ZW, He DY, Dai SM (2013) IL-18 upregulates the production of key regulators of osteoclastogenesis from fibroblast-like synoviocytes in rheumatoid arthritis. Inflammation 36(1):103–109. doi:10.1007/s10753-012-9524-8 PubMedCrossRef

44.

Karonitsch T, von Dalwigk K, Steiner CW, Bluml S, Steiner G, Kiener HP, Smolen JS, Aringer M (2012) Interferon signals and monocytic sensitization of the interferon-gamma signaling pathway in the peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum 64(2):400–408. doi:10.1002/art.33347 PubMedCrossRef

45.

van Baarsen LG, Bos WH, Rustenburg F, van der Pouw Kraan TC, Wolbink GJ, Dijkmans BA, van Schaardenburg D, Verweij CL (2010) Gene expression profiling in autoantibody-positive patients with arthralgia predicts development of arthritis. Arthritis Rheum 62(3):694–704. doi:10.1002/art.27294 PubMedCrossRef

46.

Cantaert T, van Baarsen LG, Wijbrandts CA, Thurlings RM, van de Sande MG, Bos C, van der Pouw TK, Verweij CL, Tak PP, Baeten DL (2010) Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis. Rheumatology (Oxford) 49(1):156–166. doi:10.1093/rheumatology/kep345 CrossRef

47.

Endo H, Akahoshi T, Takagishi K, Kashiwazaki S, Matsushima K (1991) Elevation of interleukin-8 (IL-8) levels in joint fluids of patients with rheumatoid arthritis and the induction by IL-8 of leukocyte infiltration and synovitis in rabbit joints. Lymphokine Cytokine Res 10(4):245–252PubMed

48.

Chen DY, Hsieh TY, Chen YM, Hsieh CW, Lan JL, Lin FJ (2009) Proinflammatory cytokine profiles of patients with elderly-onset rheumatoid arthritis: a comparison with younger-onset disease. Gerontology 55(3):250–258. doi:10.1159/000164393 PubMedCrossRef

49.

Wilke CM, Bishop K, Fox D, Zou W (2011) Deciphering the role of Th17 cells in human disease. Trends Immunol 32(12):603–611. doi:10.1016/j.it.2011.08.003 PubMedCentralPubMedCrossRef

50.

Balsa A, Del Amo J, Blanco F, Caliz R, Silva L, Sanmarti R, Martinez FG, Tejedor D, Artieda M, Pascual-Salcedo D, Oreiro N, Collado MD, Andreu JL, Graell E, Simon L, Martinez A, Mulero J (2010) Prediction of functional impairment and remission in rheumatoid arthritis patients by biochemical variables and genetic polymorphisms. Rheumatology (Oxford) 49(3):458–466. doi:10.1093/rheumatology/kep380 CrossRef

51.

Sarkar S, Cooney LA, White P, Dunlop DB, Endres J, Jorns JM, Wasco MJ, Fox DA (2009) Regulation of pathogenic IL-17 responses in collagen-induced arthritis: roles of endogenous interferon-gamma and IL-4. Arthritis Res Ther 11(5):R158. doi:10.1186/ar2838 PubMedCentralPubMedCrossRef

52.

Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S (2013) Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol 31:227–258. doi:10.1146/annurev-immunol-020711-075005 PubMedCrossRef

53.

Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69(9):1580–1588. doi:10.1136/ard.2010.138461 PubMedCrossRef

54.

Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38(1):44–48PubMedCrossRef

55.

Kay HD (1980) A new procedure to overlay diluted blood on Ficoll-hypaque gradients. J Immunol Methods 39(1–2):81–83PubMed

56.

Lanier LL, Testi R, Bindl J, Phillips JH (1989) Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med 169(6):2233–2238PubMedCrossRef

57.

Sarkar M, Varshney R, Chopra M, Sekhri T, Adhikari JS, Dwarakanath BS (2006) Flow-cytometric analysis of reactive oxygen species in peripheral blood mononuclear cells of patients with thyroid dysfunction. Cytometry B Clin Cytom 70(1):20–23. doi:10.1002/cyto.b.20082 PubMedCrossRef

Title: Role of cytolytic impairment of natural killer and natural killer T-cell populations in rheumatoid arthritis
Authors: Ashish Aggarwal
Aman Sharma
Archana Bhatnagar
Publication date: 01-08-2014
Publisher: Springer London
Published in: Clinical Rheumatology / Issue 8/2014
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-014-2641-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2014

Two Takayasu arteritis patients successfully treated with rituximab

Clinical course and outcomes of Iranian children with juvenile dermatomyositis and polymyositis

Cardiac complications of Behcet’s disease

Sjögren’s syndrome accompanied with interstitial cystitis: a case report and review of the literature

Experiences of gout-related disability from the patients’ perspective: a mixed methods study

Increased incidence of liver enzymes abnormalities in patients treated with isoniazid in combination with disease modifying and/or biologic agents

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage